Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo’s Loratadine 505(b)(2) NDA Was Properly Submitted, Firm Maintains

This article was originally published in The Tan Sheet

Executive Summary

Perrigo chose to file a 505(b)(2) NDA for its generic loratadine 10 mg tablet because at the time it submitted the application, reference listed drug Claritin still was a prescription product, the firm states in recent comments to FDA
Advertisement

Related Content

Perrigo Nets Former Pharmacia Counsel Kingma To Support New Strategy
Perrigo Nets Former Pharmacia Counsel Kingma To Support New Strategy
Perrigo Nets Former Pharmacia Counsel Kingma To Support New Strategy
Perrigo New Products Include Branded Weight-Loss Supplement, Kid’s Multi
Perrigo Loratadine 10 Mg 505(b)(2) Should Be Denied – Genpharm Petition
Perrigo Loratadine 10 Mg 505(b)(2) Should Be Denied – Genpharm Petition
Leiner Store Brand Loratadine To Begin Retail Shipments In July
Perrigo Loses Acetaminophen Supplier, Gains Loratadine Deal
Wyeth Alavert Approval Sparks Loratadine Price Wars, Fight For OTC Share
Desloratadine Patent Claims No Bar To Generic Claritin, Judge Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS095511

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel